BMY - BRISTOL MYERS SQUIBB CO

61.22
-1.120   -1.829%

Share volume: 12,411,545
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$62.34
-1.12
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
71%
Profitability 73%
Dept financing 40%
Liquidity 59%
Performance 79%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.84%
1 Month
6.25%
3 Months
17.84%
6 Months
31.12%
1 Year
2.99%
2 Year
20.23%
Key data
Stock price
$61.22
P/E Ratio 
15.38
DAY RANGE
$60.43 - $61.95
EPS 
$3.47
52 WEEK RANGE
$42.52 - $63.33
52 WEEK CHANGE
$2.34
MARKET CAP 
108.526 B
YIELD 
4.65%
SHARES OUTSTANDING 
2.036 B
DIVIDEND
$0.63
EX-DIVIDEND DATE
04-02-2026
NEXT EARNINGS DATE
07-25-2025
BETA 
-0.11
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$14,565,044
AVERAGE 30 VOLUME 
$13,968,674
Company detail
CEO: Giovanni Caforio
Region: US
Website: bms.com
Employees: 34,300
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma.

Recent news